Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03181308 | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | completed | Phase 1 | 11 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jun 24, 2020 | clinicaltrials |
| NCT03326752 | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | completed | Phase 1 | 26 | Dynavax Technologies CorporationINDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04397926 |
| Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer |
| unknown |
| Phase 1 |
| 20 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Jun 11, 2020 |
| clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 236 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02007070 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | completed | Phase 1 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 13, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT04153799 | Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 | 11 | Sun Yat-sen UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT02221739 | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 39 | NYU Langone HealthOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT04360915 | Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects | completed | Phase 1 | 24 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2020 | clinicaltrials |
| NCT02374645 | A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | completed | Phase 1 | 64 | Hutchison Medipharma LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00966472 | Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC | completed | Phase 1 | 24 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT02013219 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Apr 21, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT00921739 | Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies(ESIMRT) | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | terminated | Phase 1 | 23 | University of Maryland, BaltimoreOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT01562210 | Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC(olaparib) | completed | Phase 1 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 17 | Regeneron PharmaceuticalsINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT00097903 | Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer | completed | Phase 1 | 32 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02916745 | Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer | completed | Phase 1 | 5 | Concordia Laboratories Inc.INDUSTRY | 2 | Mar 4, 2020 | clinicaltrials |
| NCT03130881 | Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. | unknown | Phase 1 | 60 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02840994 | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 | 24 | Bavarian NordicINDUSTRY | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin(iTRAP) | withdrawn | Phase 1 | 0 | Queen Mary University of LondonOTHER | 0 | Feb 25, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02009436 | Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | completed | Phase 1 | 8 | Albert Einstein College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | completed | Phase 1 | 56 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 5 | Central European Cooperative Oncology GroupOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01059552 | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)(NSCLC) | completed | Phase 1 | 18 | Fox Chase Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jun 24, 2020source: clinicaltrials